WBA - Walgreens Boots Alliance, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
40.72
+0.40 (+0.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close40.32
Open40.25
Bid40.28 x 800
Ask40.40 x 800
Day's range39.75 - 41.10
52-week range39.41 - 64.50
Volume6,489,129
Avg. volume7,485,868
Market cap36.072B
Beta (5Y monthly)0.89
PE ratio (TTM)9.99
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.83 (4.54%)
Ex-dividend date17 Feb 2020
1y target estN/A
  • Company News for Apr 3, 2020
    Zacks

    Company News for Apr 3, 2020

    Companies In The News Are: NEPT, BMRA, LK, WBA

  • Walgreens shares fall as coronavirus pandemic hits store sales
    Reuters

    Walgreens shares fall as coronavirus pandemic hits store sales

    The company said retail sales in the United States dropped after March 21, before which consumers were stockpiling items in preparation for a lockdown. Meanwhile, retail sales at its UK business has plummeted 65% in the last 10 days. Walgreens executives said the situation was temporary as they fielded several questions from analysts on a conference call.

  • Walgreens Slumps After Executives Flag Downturn in Sales
    Bloomberg

    Walgreens Slumps After Executives Flag Downturn in Sales

    (Bloomberg) -- Walgreens Boots Alliance Inc. sank after executives said sales have started to decline at its drugstores as a result of the coronavirus pandemic, though the full impact on its business won’t be known for months.U.S. consumers had raced early last month to stock up on drugs, cleaning supplies and toilet paper as they prepared to stay at home to avoid getting or spreading Covid-19. Now, that rush appears to be ebbing.In the first three weeks of March, Walgreens’ comparable sales rose about 26%, Chief Financial Officer James Kehoe said on a call Thursday with Wall Street analysts, adding that health and grocery sales surged while discretionary categories like beauty slumped. However, sales began to fall in the last 10 days of March, declining at a mid-teens percentage rate.“Obviously, if this trend continues for an extended period, it will quickly offset the sales uplift seen in the first 21 days of March,” Kehoe said.Kehoe said the pharmacy business experienced similar trends, though less pronounced, with patients refilling prescriptions early.Shares fell 7% to $40.01 at 10:27 a.m. in New York. Since the beginning of 2020, the stock had declined 27% through the close of trading Wednesday.Earlier Thursday, Walgreens posted better-than-expected results for its second quarter but cautioned that the Covid-19 pandemic makes the future uncertain. The Deerfield, Illinois-based company said it would update its financial guidance in its next quarterly report. Previously, it had projected roughly flat growth in adjusted earnings per share.Chief Executive Officer Stefano Pessina said while the company’s second-quarter results were better than expectations, “it is too early to know what the net impact of the Covid-19 pandemic will be on our performance for the year.”Early SignsThe comments from Walgreens offer an early look at how businesses have been faring since the start of the coronavirus pandemic. While the company’s quarter ended on Feb. 29, before the worst of the Covid-19 outbreak in the U.S. and the most ambitious of the social-distancing efforts to contain it, executives indicated on the call with analysts that recent weeks have become more challenging.Walgreens executives stressed they think the situation is temporary, but Pessina said if the pandemic lasts more than a month its effects will be longer-lasting.“The world will be different later on,” he said. “Many things will have changed, their habits will be different.”Walgreens had already been trying to bolster its digital strategy before the outbreak. It has since made delivery free on its website and expanded a partnership with delivery service Postmates, among other efforts.In its second-quarter report, Walgreens said comparable sales at its U.S. stores rose 2.7% from a year earlier. At the pharmacy counter, sales rose 5.3%, which the company attributed to more expensive prescription drugs, more prescriptions filled and growth in its specialty business.Walgreens removed e-cigarettes from its U.S. stores last fall and has said it will de-emphasize tobacco. Those decisions weighed on results, as comparable retail sales rose 0.6% in the quarter, or 1.9% when excluding these products.Second-quarter adjusted earnings per share of $1.52, down from $1.64 a year earlier but better than the $1.46 Wall Street analysts expected, on average.(Adds more comments from Walgreens executives beginning in 10th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
    Zacks

    Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down

    The coronavirus outbreak had an immaterial impact on Walgreens Boots' (WBA) second-quarter fiscal 2020 results.

  • Walgreens Boots Stock Falls 8%
    Investing.com

    Walgreens Boots Stock Falls 8%

    Investing.com - Walgreens Boots (NASDAQ:WBA) Stock fell by 7.59% to trade at $39.71 by 12:40 (16:40 GMT) on Thursday on the NASDAQ exchange.

  • Walgreens Boots Alliance (WBA) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Walgreens Boots Alliance (WBA) Q2 Earnings and Revenues Beat Estimates

    Walgreens (WBA) delivered earnings and revenue surprises of 4.83% and 1.48%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Walgreens Boots Earnings, Revenue Beat in Q2
    Investing.com

    Walgreens Boots Earnings, Revenue Beat in Q2

    Investing.com - Walgreens Boots (NASDAQ:WBA) reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.

  • Moody's: Clinical trials troubled amid coronavirus outbreak, drug sales not so much
    Yahoo Finance

    Moody's: Clinical trials troubled amid coronavirus outbreak, drug sales not so much

    Anecdotal reports of clinical drug trials being disrupted by the coronavirus outbreak have caused concern for the life sciences sector at large, though it appears vaccine trials for COVID-19 won’t be affected, according to Moody’s.

  • Why Walgreens Boots Alliance (WBA) Might Surprise This Earnings Season
    Zacks

    Why Walgreens Boots Alliance (WBA) Might Surprise This Earnings Season

    Walgreens Boots Alliance (WBA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Walgreens Boots Stock Falls 4%
    Investing.com

    Walgreens Boots Stock Falls 4%

    Investing.com - Walgreens Boots (NASDAQ:WBA) Stock fell by 4.05% to trade at $43.87 by 12:39 (16:39 GMT) on Wednesday on the NASDAQ exchange.

  • Can Retail Pharmacy USA Aid Walgreen Boots' (WBA) Q2 Earnings?
    Zacks

    Can Retail Pharmacy USA Aid Walgreen Boots' (WBA) Q2 Earnings?

    Solid prescription volume growth and brand inflation anticipated to have aided Walgreen Boots' (WBA) Retail Pharmacy USA performance in Q2.

  • Boots UK to donate over 200,000 toiletries to NHS and vulnerable people
    Yahoo Finance UK

    Boots UK to donate over 200,000 toiletries to NHS and vulnerable people

    Thousands of bathroom essentials will be distributed to NHS staff as well as schools and food banks to support the vulnerable.

  • Walgreens Boots Stock Rises 4%
    Investing.com

    Walgreens Boots Stock Rises 4%

    Investing.com - Walgreens Boots (NASDAQ:WBA) Stock rose by 4.03% to trade at $46.98 by 10:12 (14:12 GMT) on Tuesday on the NASDAQ exchange.

  • JPMorgan, Wells Fargo, Walgreens, Constellation Brands and Nike are part of Zacks Earnings Preview
    Zacks

    JPMorgan, Wells Fargo, Walgreens, Constellation Brands and Nike are part of Zacks Earnings Preview

    JPMorgan, Wells Fargo, Walgreens, Constellation Brands and Nike are part of Zacks Earnings Preview

  • Buy Walgreens (WBA) Stock Ahead of its Q2 Fiscal 2020 Earnings Release?
    Zacks

    Buy Walgreens (WBA) Stock Ahead of its Q2 Fiscal 2020 Earnings Release?

    Should investors think about buying Walgreens stock with the pharmacy and retail giant set to report its Q2 fiscal 2020 earnings results on Thursday, April 2?

  • Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for

    Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Here's how U.S. coronavirus testing is working
    Yahoo Finance

    Here's how U.S. coronavirus testing is working

    The FDA has now approved two methods of testing swab samples, with several more in queue.

  • Walgreens Boots Alliance (WBA) in Focus: Stock Moves 6.5% Higher
    Zacks

    Walgreens Boots Alliance (WBA) in Focus: Stock Moves 6.5% Higher

    Walgreens Boots Alliance (WBA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more